Richard Law CFA
Stock Analyst at Goldman Sachs
(3.56)
# 2,206
Out of 4,512 analysts
128
Total ratings
46.9%
Success rate
8.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COAG Hemab Therapeutics Holdings | Maintained: Buy | $36 → $46 | $39.51 | +16.43% | 2 | Jul 13, 2026 | |
| VRDN Viridian Therapeutics | Rated: Buy | $35 → $39 | $18.99 | +105.37% | 10 | Jun 29, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Hold | $110 | $129.89 | -15.31% | 6 | Jun 10, 2026 | |
| MLYS Mineralys Therapeutics | Maintained: Buy | $42 | $27.59 | +52.23% | 12 | Jun 3, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Hold | $18 | $28.15 | -36.06% | 4 | Jun 1, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $27 → $23 | $11.85 | +94.09% | 9 | May 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Sell | $11 → $12 | $20.41 | -41.21% | 8 | May 11, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Hold | $34 → $38 | $38.53 | -1.38% | 5 | May 8, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $30 → $34 | $28.07 | +21.13% | 3 | May 7, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Sell | $3 | $3.72 | -19.35% | 7 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $4 | $9.29 | -56.94% | 3 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $83.67 | -19.92% | 5 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $29 → $33 | $27.12 | +21.68% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $120 → $135 | $123.94 | +8.92% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $30 → $33 | $38.12 | -13.43% | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $31 | $21.38 | n/a | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $47 | $31.00 | n/a | 4 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $62 → $63 | $50.63 | n/a | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $37 | $110.40 | n/a | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $76 | $13.02 | n/a | 7 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $21.98 | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $14 | $3.16 | n/a | 3 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 | $8.10 | n/a | 5 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $10 | $3.92 | n/a | 2 | Feb 24, 2023 |
Hemab Therapeutics Holdings
Jul 13, 2026
Maintained: Buy
Price Target: $36 → $46
Current: $39.51
Upside: +16.43%
Viridian Therapeutics
Jun 29, 2026
Rated: Buy
Price Target: $35 → $39
Current: $18.99
Upside: +105.37%
Protagonist Therapeutics
Jun 10, 2026
Maintained: Hold
Price Target: $110
Current: $129.89
Upside: -15.31%
Mineralys Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: $42
Current: $27.59
Upside: +52.23%
Bicara Therapeutics
Jun 1, 2026
Maintained: Hold
Price Target: $18
Current: $28.15
Upside: -36.06%
Olema Pharmaceuticals
May 12, 2026
Maintained: Buy
Price Target: $27 → $23
Current: $11.85
Upside: +94.09%
MoonLake Immunotherapeutics
May 11, 2026
Maintained: Sell
Price Target: $11 → $12
Current: $20.41
Upside: -41.21%
Celldex Therapeutics
May 8, 2026
Maintained: Hold
Price Target: $34 → $38
Current: $38.53
Upside: -1.38%
Arcus Biosciences
May 7, 2026
Maintained: Buy
Price Target: $30 → $34
Current: $28.07
Upside: +21.13%
Rocket Pharmaceuticals
Mar 27, 2026
Maintained: Sell
Price Target: $3
Current: $3.72
Upside: -19.35%
Mar 5, 2026
Maintained: Sell
Price Target: $4
Current: $9.29
Upside: -56.94%
Mar 1, 2026
Maintained: Buy
Price Target: $67
Current: $83.67
Upside: -19.92%
Feb 27, 2026
Maintained: Hold
Price Target: $29 → $33
Current: $27.12
Upside: +21.68%
Nov 18, 2025
Maintained: Buy
Price Target: $120 → $135
Current: $123.94
Upside: +8.92%
Jul 24, 2025
Maintained: Hold
Price Target: $30 → $33
Current: $38.12
Upside: -13.43%
Aug 15, 2023
Maintained: Hold
Price Target: $36 → $31
Current: $21.38
Upside: n/a
Aug 9, 2023
Maintained: Hold
Price Target: $47
Current: $31.00
Upside: n/a
Aug 8, 2023
Maintained: Hold
Price Target: $62 → $63
Current: $50.63
Upside: n/a
Aug 4, 2023
Maintained: Hold
Price Target: $36 → $37
Current: $110.40
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $76
Current: $13.02
Upside: n/a
May 12, 2023
Reiterated: Hold
Price Target: $11
Current: $21.98
Upside: n/a
May 5, 2023
Maintained: Hold
Price Target: $15 → $14
Current: $3.16
Upside: n/a
May 5, 2023
Maintained: Buy
Price Target: $61
Current: $8.10
Upside: n/a
Feb 24, 2023
Upgraded: Hold
Price Target: $10
Current: $3.92
Upside: n/a